SINTX Technologies Inc

SINTX Technologies Inc(SINT)の株式分析

$1.560

-0.058 (-3.70%)終値時点

Loading chart…
高値
1.640
始値
1.640
出来高加重平均価格
1.58
出来高
41.03K
時価総額
3.17M
安値
1.550
売買代金
64.96K
EV/EBITDA(TTM)
-0.31

SINTX Technologies, Inc. is an advanced ceramics company that develops and commercializes materials, components, and technologies for medical and agribiotech applications. It is engaged in the research, development, and manufacturing of silicon nitride. Its core business includes biomedical applications and antipathogenic applications. It has been focused on medical grade silicon nitride. Spinal implants made from its silicon nitride have been implanted in humans. This established use, along with its inherent resistance to bacterial adhesion and bone affinity suggests that it may also be suitable in other fusion device applications such as arthroplasty implants, foot wedges, and dental implants. Its composition of silicon nitride antipathogenic powder may enable manufacturing surfaces that inactivate pathogens, thereby limiting the spread of infection and disease. It manufactures advanced ceramic powders and components in its manufacturing facilities based in Salt Lake City, Utah.

sintx.com

AI分析 of SINTX Technologies Inc (SINT)

売り

SINTX Technologies Inc is not a good buy right now due to its very low RSI of 23.718, indicating oversold conditions, and a significant year-to-date decline of 58.73%. The stock is currently trading at $1.56, which is only 5.2% above its 52-week low of $1.40, suggesting limited upside potential. Additionally, the company has reported substantial net losses, with a net income of -$3,632,000 in Q2 2026, raising concerns about its financial stability. The main risk is its high debt-to-equity ratio of 11.73% in Q1 2026, indicating potential liquidity issues.

バリュエーション指標

SINTX Technologies Inc(SINT)の現在の予想PERは0.00で、5年平均は-19.40です。

予想PER

適正
5年平均 P/E
-19.40
現在のP/E
0.00
割高
59.35
割安
-98.14

予想EV/EBITDA

適正
5年平均 EV/EBITDA
-0.32
現在のEV/EBITDA
-0.31
割高
0.29
割安
-0.94

予想PSR

適正
5年平均 P/S
4.14
現在のP/S
2.03
割高
8.10
割安
0.19

Alphio AI による SINT の価格シナリオ

シナリオ価格は本年の最終月次予想レンジです。確率はモデルの固定ウェイト(25 / 50 / 25)であり、保証ではありません。

強

強気

強気 · 25%SINT

$2.63

シナリオ価格

基

基本

基本 · 50%SINT

$1.91

シナリオ価格

弱

弱気

弱気 · 25%SINT

$1.46

シナリオ価格

イベントタイムライン

2026-11-05 (ET)

17:30:00

SINTX Technologies Reports Q3 Revenue of $2.19M

2026-10-01 (ET)

09:30:00

Sintx Technologies Reports $2.2M Revenue for Q3

2026-08-13 (ET)

06:30:00

Selling Stockholders Plan to Sell 1.27M Shares of Common Stock

2026-06-25 (ET)

06:30:00

Sintx Technologies Files to Sell 5.82M Shares of Common Stock

2026-06-22 (ET)

10:00:00

Sintx Technologies Secures Over $3.2M in Orders

ニュース

SINT のよくある質問 — Alphio AI が回答

SINTX Technologies, Inc. is an advanced ceramics company that develops and commercializes materials, components, and technologies for medical and agribiotech applications. It is engaged in the research, development, and manufacturing of silicon nitride. Its core business includes biomedical applications and antipathogenic applications. It has been focused on medical grade silicon nitride. Spinal implants made from its silicon nitride have been implanted in humans. This established use, along with its inherent resistance to bacterial adhesion and bone affinity suggests that it may also be suitable in other fusion device applications such as arthroplasty implants, foot wedges, and dental implants. Its composition of silicon nitride antipathogenic powder may enable manufacturing surfaces that inactivate pathogens, thereby limiting the spread of infection and disease. It manufactures advanced ceramic powders and components in its manufacturing facilities based in Salt Lake City, Utah. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).

SINTX Technologies Inc is not a good buy right now due to its very low RSI of 23.718, indicating oversold conditions, and a significant year-to-date decline of 58.73%. The stock is currently trading at $1.56, which is only 5.2% above its 52-week low of $1.40, suggesting limited upside potential. Additionally, the company has reported substantial net losses, with a net income of -$3,632,000 in Q2 2026, raising concerns about its financial stability. The main risk is its high debt-to-equity ratio of 11.73% in Q1 2026, indicating potential liquidity issues.

コミュニティ

もっと見る ↗

投稿はまだありません

登録またはログインして議論に参加

関連記事

本ページは調査目的であり、投資助言ではありません。モデルは誤ることがあります。過去の実績は将来の成果を保証しません。

取引を始める